Lupin Ltd News

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Lupin gets tentative US FDA approval for generic prostate cancer drug

The tentative approval allows Lupin to market the generic prostate cancer treatment in the US after patent and exclusivity barriers expire

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Stocks to Watch today: RIL, Lupin, Wipro, Asian Paints, Ireda, Tata Elxsi

Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today

Stocks to Watch today: Eicher Motors, NTPC, TVS Motor, Groww, Hindalco

Stocks to Watch today, May 25, 2026: Shares of oil marketing companies will remain in focus today after petrol and diesel prices were raised by ₹2.61-2.71 per litre on Monday

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Stocks to watch today: Adani stocks, JSW Steel, Indian Oil, Astral, Lupin

Stocks to Watch today, May 19, 2026: Adani Group stocks, Indian Oil, JSW Steel, Astral, and Lupin are some of the key stocks to watch today

Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto

Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today

Nifty Midcap Select index hits record high, rallies 13% in one month

The Nifty Midcap Select index hit a new high of 14,223.90, soaring 2% and surpassing its previous high of 14,118 touched on December 1, 2025.

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Nifty Apr F&O rollovers hint at cautious stance; ONGC among stocks in focus

The Nifty rollovers to May were below average, suggesting a likely cautious stance among participants and slight hesitation to carry forward aggressive bets, says Axis Securities.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Lupin's US arm signs $30 million litigation settlement with Humana Inc

Pharma major Lupin Ltd on Friday said its arm Lupin Pharmaceuticals, Inc USA has entered into a USD 30 million settlement agreement with Humana Inc for litigation over alleged anti-competitive practices. Lupin Pharmaceuticals, Inc USA (LPI) has been involved in multiple civil lawsuits alleging anti-competitive behaviour related to certain products and violation of federal and state antitrust laws. These multiple civil lawsuits were then combined into the collection of similar cases referred to as 'In Re Generic Pharmaceuticals Antitrust Litigation' located in Philadelphia, Pennsylvania, Lupin said in a regulatory filing. "While LPI denies the allegations, bu considering that other defendants have recently settled the case and in order to avoid the costs and uncertainties of continued litigation, LPI has entered into a settlement agreement with one of the plaintiffs namely Humana Inc. (Humana)," it added. Under the terms of the agreement, LPI will pay USD 30 million in consideration

Lupin arm settles US antitrust litigation with Humana for $30 million

Lupin says its US subsidiary will pay $30 million to Humana to settle antitrust claims, adding the amount has already been provided for and does not impact current financials

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Stocks to Watch today: TCS, Info Edge, ITC Hotels, Lupin, NHPC, KEC Intl

Stocks to Watch today, April 9, 2026: ITC Hotels, NHPC, KEC International, TCS, and Info Edge are some of the key stocks to watch today

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Stocks to Watch today: Acme Solar, Indian Oil, Power Grid, Glenmark Pharma

Stocks to Watch today, April 2, 2026: Lupin, Inox Clean Energy, Latent View Analytics, Jubilant FoodWorks, and Lemon Tree Hotels are among the top stocks to watch during today's trading session

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Pharma major Lupin Ltd on Tuesday said it has received tentative approval from the US health regulator for its generic version of Sugammadex injection used for reversing the effects of muscle relaxants given during surgery. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Sugammadex Injection of strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial, Lupin said in a regulatory filing. The USFDA has tentatively approved Lupin's Sugammadex injection of the specified strengths as bioequivalent to Merck's Bridion injection, it added. It is used for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery, the company said.